RedHill Biopharma Ltd.
RDHL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $3 | $5 | $16 | $23 |
| - Cash | $3 | $3 | $5 | $2 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $2 | $12 | $21 |
| Revenue | $2 | $2 | $3 | $3 |
| % Growth | 0% | -25.4% | 0% | – |
| Gross Profit | $1 | $1 | $2 | $2 |
| % Margin | 60.6% | 60.6% | 67.3% | 67.3% |
| EBITDA | -$2 | -$2 | -$2 | -$2 |
| % Margin | -103.2% | -103.2% | -68.7% | -66.4% |
| Net Income | -$2 | -$2 | -$3 | -$3 |
| % Margin | -101.3% | -101.3% | -94.7% | -94.7% |
| EPS Diluted | -1 | -1 | -1 | -1 |
| % Growth | 0% | 0% | 0% | – |
| Operating Cash Flow | -$3 | -$3 | -$2 | -$2 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$3 | -$3 | -$2 | -$2 |